Clinical Trials Logo
  1. Home
  2. Hypercalcemia
  3. NCT06467877
  4. Details
NCT06467877 Clinical Trial

Causes, Characteristics and Treatment of Hypercalcemia in the Emergency Room of a German Hospital

Hypercalcemia Clinical Trial

Official title:
Retrospective Analysis of Causes, Clinical Presentation and Treatment in Patients With Hypercalcaemia in the Emergency Department of a Tertiary German Hospital

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT06467877
Other study ID # V1.0-13.05.2024
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 1, 2010
Est. completion date December 31, 2025

Study information
Verified date June 2024
Source University of Cologne
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients with hypercalcemia were identified in the patient population of a German emergency department during a 11 year time period and studied regarding reproducibility of elevated calcium values, causes of hypercalcemia, symptoms. acute renal injury, mortality and treatment response.

Description:

Patients, who presented to the emergency department of a tertiary German hospital with a total calcium of ≥2.65 mmol/l between January 2010 and March 2021, was retrospectively studied. From the electronic patient records we analyzed if the elevated calcium values were reproducible in follow-up measurements, identified the cause of hypercalcemia, listed the symptoms, investigated a correlation between calcium and creatinine values to study acute renal injury directly due to hypercalcemia, calculated the mortality rate stratified by the calcium value on presentation and studied the treatment response regarding lowering calcium values by different treatments.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 200
Est. completion date December 31, 2025
Est. primary completion date March 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age > 18 years - Total calcium = 2.65 mmol/l - Female and male Exclusion Criteria: - Age < 18 years - Total calcium < 2.65 mmol/

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Germany Department II of Internal Medicine,University of Cologne Cologne

Sponsors (1)
Lead Sponsor Collaborator
University of Cologne

Country where clinical trial is conducted

Germany, 

Outcome
Type Measure Description Time frame Safety issue
Primary Course of total calcium values Overview of total calcium values within 5 days 5 days after enrollment
Secondary Reproducibility of elevated calcium values Determination of cause of hypercalcemia, of symptoms, of treatment response. In dependence of hospital stay, kann be determined later than 5 days after enrollment 5 days after enrollment
Secondary Correlation creatinine calcium Determination of correlation between calcium and creatinine. 5 days after enrollment
Secondary Mortality occurence of death within of 5 days after enrollment 5 days after enrollment
See also
  Status Clinical Trial Phase
Withdrawn NCT02711059 - Insulin Resistance in Primary Hyperparathyroidism N/A
Recruiting NCT05585593 - Registry for Hypoparathyroidism Wuerzburg
Terminated NCT01725113 - Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol Phase 4
Completed NCT01460030 - An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism Phase 3
Completed NCT00325104 - Cinacalcet to Treat Familial Primary Hyperparathyroidism Phase 3
Recruiting NCT03935984 - Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity Phase 4
Withdrawn NCT01329666 - Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D Phase 2/Phase 3
Completed NCT00891813 - Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Phase 4
Completed NCT00674154 - Effect of Vitamin D Treatment in Primary Hyperparathyroidism Phase 2/Phase 3
Completed NCT04299425 - Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy N/A
Completed NCT00975221 - Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy Phase 3
Withdrawn NCT03516747 - Preoperational Fine Needle Aspiration of Pathological Parathyroid Gland N/A
Completed NCT00485706 - Arterial Stiffness and Decreased Bone Buffering Capacity in Hemodialysis Patients N/A
Recruiting NCT01647503 - Differentially Expressed Proteins in Sporadic Parathyroid Tumors N/A
Completed NCT01042626 - Oral Peptones Load in Normocalcemic and Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects N/A
Not yet recruiting NCT01021280 - Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome N/A
Not yet recruiting NCT01226810 - The Novel Approach of Minimally Invasive Parathyroid Surgery Requires Precise Identification and Localization of the Lesion Prior to Exploration N/A
Terminated NCT00415584 - Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients Phase 1/Phase 2
Completed NCT00581828 - Does Treatment of Hypovitaminosis D Increase Calcium Absorption? Phase 4
Completed NCT00126386 - Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community N/A